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neck region
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Claes Mercke1, Erik Olsson5, Lena Wiren3 and Gudmundur Johannsson3*Abstract
Background: Adult patients with hypothalamic-pituitary disorders have compromised quality of life (QoL). Whether
this is due to their endocrine consequences (hypopituitarism), their underlying hypothalamic-pituitary disorder or
both is still under debate. The aim of this trial was to measure quality of life (QoL) in long-term cancer survivors
who have received a radiation dose to the basal part of the brain and the pituitary.
Methods: Consecutive patients (n=101) treated for oropharyngeal or epipharyngeal cancer with radiotherapy
followed free of cancer for a period of 4 to10 years were identified. Fifteen patients (median age 56 years) with no
concomitant illness and no hypopituitarism after careful endocrine evaluation were included in a case-control study
with matched healthy controls. Doses to the hypothalamic-pituitary region were calculated. QoL was assessed using
the Symptom check list (SCL)-90, Nottingham Health Profile (NHP), and Psychological Well Being (PGWB)
questionnaires. Level of physical activity was assessed using the Baecke questionnaire.
Results: The median accumulated dose was 1.9 Gy (1.5–2.2 Gy) to the hypothalamus and 2.4 Gy (1.8–3.3 Gy) to the
pituitary gland in patients with oropharyngeal cancer and 6.0–9.3 Gy and 33.5–46.1 Gy, respectively in patients with
epipharyngeal cancer (n=2). The patients showed significantly more anxiety and depressiveness, and lower vitality,
than their matched controls.
Conclusion: In a group of long time survivors of head and neck cancer who hade received a low radiation dose to
the hypothalamic-pituitary region and who had no endocrine consequences of disease or its treatment QoL was
compromised as compared with well matched healthy controls.
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Hypopituitarism in adults is mostly due to hypothalamic-
pituitary tumours and its treatment with surgery,
radiotherapy or both. Although carefully replaced with
glucocorticoids, thyroxine and sex steroids, hypopituit-
arism and untreated growth hormone (GH) deficiency* Correspondence: Gudmundur.Johannsson@gu.se
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reproduction in any medium, provided the orin adults has been associated with compromised qual-
ity of life (QoL) [1]. The reduced well-being experi-
enced by many patients with hypopituitarism and
untreated GH deficiency has been one of the most
compelling arguments supporting GH replacement in
adults [2]. This has, however, been questioned by some
studies suggesting that the pituitary disease itself or
the choice of therapy may explain the reduced QoL in
adult patients with hypopituitarism and untreated GH
deficiency [3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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hypopituitarism and GH deficiency in adults [4]. When
brain areas are included in the radiation field, late reac-
tions with vascular and neuronal damage will occur. It is
well established that doses of more than 18–20 Gy to the
hypothalamic-pituitary area will cause neuroendocrine
consequences and reduced QoL and cognitive function.
This is particularly well established in adult patients with
pituitary adenomas who have received radiotherapy in
doses approximating 40 Gy [1]. These patients suffer
from low energy levels, lack of vitality, mental fatigue,
poor memory and concentration, and increased anxiety
and emotional reactions [1]. In such patients it is not
possible to differentiate to what extent the effects on
QoL and cognitive function are endocrine consequences
of radiotherapy, and to what extent they are due to
radiation-induced brain damage in the hypothalamus.
The endocrine consequences of radiotherapeutic
effects on the hypothalamus are dose related [5]. Al-
though low dose exposure (<100mGy per fraction) has
recently been suggested to cause cognitive impairment
in children [6], information is unavailable on such low
dose exposure in adults. Estimations concerning an in-
crease in secondary malignancies after low dose have
been made [7], but other biological late effects, such as
endocrine effects or factors known to affect QoL, have
not been well studied.
The prognosis for patients with cancers of the head
and neck has improved during recent years allowing for
a more long-term follow-up of these patients. The
causes of this include the introduction of hyper fractio-
nated accelerated radiotherapy (EBRT) and brachyther-
apy (BT) in combination with chemotherapy [8]. BT is
often replaced by intensity modulated radiotherapy
(IMRT). Irrespective of the radiotherapy technique used
in patients with cancers of the head and neck, a small
proportion of the dose will reach the basal part of the
brain. Earlier studies have shown disease specific long-
term consequences of the disease and its treatment
[9-12]. However, in these studies the neuroendocrine
consequences of radiation to the basal part of the brain
have not been considered as a confounder.
The present patient population was therefore used as a
model to explore our research hypothesis that a relatively
low dose of radiotherapy towards the adult basal brain
will have a long-term impact on QoL independently of
the possible neuroendocrine consequences of such ther-
apy. The data from this study of long-term survivors of
head and neck cancer may support this hypothesis.
Methods
Patients
From the local database of the Department of Oncology
in 2002, 101 individuals with head and neck cancerswere identified. Adults between 20 and 85 years of age
who had received radiotherapy for their cancer 4–10
years earlier were eligible for the study. All patients had
received radiotherapy to the neck and the base of the
skull; the histopathology for all tumours was squamous
cell carcinoma. Patients were excluded for further ana-
lysis if they had significant nutritional difficulties or any
other major consequences after previous treatment of
the primary disorder, had significant pulmonary disease
or active malignancy, or were dependent regarding activ-
ities of daily living. Patients with a known neuroendo-
crine disorder, such as a gross hypothalamic-pituitary
lesion or previously verified anterior pituitary hormone
deficiency, were also excluded from further analysis
(Figure 1).
Using the above selection criteria, 58 survivors were
identified and invited to attend a pre-study visit to
finalize their inclusion in the study. Clinical endocrine
and evaluation was performed. Forty-eight patients came
to this first visit. Fifteen patients without endocrine or
concomitant disorders or relapse of cancer then con-
sented to be included in the case-controlled study. Me-
dian time from radiation treatment to performance of
the study was 6 years (range 4–10 years). See Table 1
for a further summary of patients’ characteristics.
Fifteen healthy controls matched for age, sex, BMI,
and social status were recruited. Relatives or close
friends were selected as controls in order to adjust for
socioeconomic status. Oral and written informed con-
sent was obtained from patients and controls before
entering the study. The study was approved by the Ethics
Committee of the University of Gothenburg (No. S644-01).
Cancer treatment
All patients had received external-beam radiotherapy
(EBRT) with a beam quality of 4–6 MV from linear
accelerators (Varian) using CT-assisted 3-D dose plan-
ning (Cadplan System). The primary target volume was
defined as gross target volume (GTV) with a margin of
1.5–2 cm. An elective target volume was also defined,
mainly in the neck region. This means that treatment
was divided into two parts, one cranial and one lower
(neck), with a division at the level of the hyoid bone. In
the lower volume there was a central shielding of the
larynx, which also meant shielding of the central part of
the thyroid gland. In treatment of the oropharynx the
cranial border is at the level of the palate, and when
treating the epipharynx the border is at the top of the
sella turcica. The dose from EBRT was either 40.8 Gy or
64.6 Gy (specified at the isocenter) to the primary target
volume according to tumour stage by use of hyper frac-
tionated, accelerated fractionation. The schedule used
was 1.7 Gy twice a day. There was a pause for 8–10 days
after either 34.0 or 40.8 Gy. The dose to the elective
Figure 1 The trial profile. From the patient group participating in the screening, survivors were selected in order to make an extended
case-control study. In this process patients more than 65 years or with any concomitant disease discovered during the screening process were
excluded. Median time from radiation treatment to the performance of the study was 6 years with range 4-10 years. For characteristics of the
patients in the case control-study, see Table 1.
Table 1 Patient characteristics, treatment and, radiotherapy doses in growth hormone sufficient adults who have
received a radiation dose towards the basal part of the brain1









EBRT + BT* Dose (Gy)
Pituitary EBRT + BT
Dose (Gy)
1 m 32 Tonsil /T1N0M0 No 25 40.8 /40.8-0 0.9 + 0.7 =1.6 1.3 +0.7= 2.0
2 m 56 Tonsil/T3N3M0 Yes 12 64.6 /64.6-40.8 1.6 + 0.3 = 1.9 2.2 +0.3 = 2.5
3 f 53 Tonsil/T2N0M0 No 27 40.8 /40.8-40.8 1.1 + 0.7 = 1.8 1.3 +0.8 = 2.1
4 f 51 Epipahr/T2N1M0 Yes 6 61.2 /61.2-40.8 8.1 + 1.2 = 9.3 44.2 +1.9 = 46.1
5 m 50 Tonsil/T1N1M0 Yes 25 40.8 /40.8-64.6 1.2 + 0.7 = 1.9 1.7 +0.7 = 2.4
6 m 66 Epipahr/T2N0M0 No 6 61.2 /40.8-40.8 4.8 + 1.2 = 6.0 31.6 +1.9 = 33.5
7 m 55 Tonsil/T3N0M0 Yes 15 64.6 /40.8-40.8 1.8 + 0.4 = 2.2 2.3 +0.4 = 2.7
8 f 54 Tonsil /T2N2M0 Yes 27 40.8 /40.8-64.6 1.2 + 0.7 = 1.9 1.7 +0.8 = 2.5
9 m 55 Tonsil/T3N0M0 Yes 12 64.6 /40.8-40.8 1.5 + 0.3 = 1.8 2.1 + 0.3 = 2.4
10 m 59 Orophar/T2N0M0 No 0 50.0 /50.0-50.0 2.0 + 0 = 2.0 2.7 + 0 = 2.7
11 m 58 Necklgl/TxN1M0 Yes 0 64.6 /40.8-64.6 2.0 + 0 = 2.0 3.3 + 0 = 3.3
12 m 65 Tonsil/T4N0M0 Yes 12 64.6 /40.8-40.8 1.2 + 0.3 = 1.5 1.9 + 0.3 = 2.2
13 m 66 Tonsil/T2N2M0 Yes 12 64.6 /40.8-64.6 1.5 + 0.3 = 1.8 2.1 + 0.3 = 2.4
14 f 63 Tonsil/T2N0M0 No 26 40.8 /40.8-40.8 0.8 + 0.7 = 1.5 1.0 + 0.8 = 1.8
15 m 61 Tonsil/T4N0M0 Yes 12 64.6 /40.8-40.8 2.0 + 0.3 = 2.3 2.6 + 0.3 = 2.9
1Abbreviations: BT = brachytherapy, r = right side of neck, l = left side of neck, EBRT = external beam radiotherapy, m = male, f = female.
* The brachytherapy dose contribution was estimated to be 1.2 Gy to the hypothalamus and 1.9 Gy to the pituitary for patients 4 and 6. For all other patients,
brachytherapy doses to the hypothalamus was 2.7% and to the pituitary 2.9%, estimated from calculations performed on 6 patients with cancer in the tonsil.
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schedule.
In addition to EBRT, 13 patients who qualified for the
case-controlled phase received a brachytherapy (BT)
boost after the EBRT. BT was delivered with an intersti-
tial 192Ir wire-loop technique, using low dose rate. The
target volume was gross target volume (GTV) with a
margin of some millimetres. The BT dose was pre-
scribed as 85% of the mean dose calculated in centrally
located points and a total dose of 6-26 Gy was given
depending on tumour stage.
For all T3–T4 and N positive tumours, the dose to the
primary target aimed at 64 Gy. For T1 and T2 sites, EBRT
was stopped at 40.8 Gy followed by BT, which delivered
an additional dose of 20–25 Gy toward the target. For T3
and T4 tumours, an external dose of 64.6 Gy was boosted
with BT with an additional 10–12 Gy. All node-negative
sites had EBRT stopped at 40.8 Gy (Figures 2 and 3). BT
techniques were used as previously described [13]. The
balance between the dose delivered by EBRT and BT was
determined for sparing normal tissue around the tumour
(e.g., the salivary glands, oral mucosa and mandible) for
T1 and T2 tumours. T3 and T4 tumours are considered
to be so bulky that a higher dose than is generallyFigure 2 The sagittal view of the dose distribution of the external be
of interest and isodose lines are presented. Abbreviations: 2= Gross target
6= hypothalamus.considered reasonable to deliver with EBRT should be
given; BT in this region can be considered the ultimate
boost [14].
Patients with stage T2N1–T4 tumours (n=35 at
screening and n=10 in the case-controlled study) also
received one cycle of induction chemotherapy with
platinol 100 mg/m2 day 1 and 5-fluorouracil (5-FU)
1000 mg/m2 day 1–5 three weeks prior to radiotherapy.
Determination of the dose to the basal part of the brain
In the 15 patients in the case-controlled phase of the
study, the total dose (i.e., the dose from both the EBRT
and the BT) was calculated from the CT-based dose
plans (Figure 4).
The two volumes of interest (hypothalamus and pituit-
ary) were identified from the CT scans. The dose to the
basal part of the brain, pituitary, and hypothalamus was
calculated. For seven patients, including the two epi-
pharynx patients, the mean EBRT dose to the hypothal-
amus and pituitary was determined from the treatment
planning system. EBRT was individually planned in three
dimensions for these patients, based on the CT imaging
results. For the other eight patients, the distances from
the field edges to the organs of interest were determinedam radiotherapy from patients with cancer of the tonsil. Volumes
volume (GTV), 3=Planning target Volume (PTV), 4=medulla, 5= pituitary,
Figure 3 The sagittal view of the dose distribution of the external beam of patients with cancer of the epipharynx. Volumes of interest
and isodose lines are presented. Abbreviations: 2= Gross target volume (GTV), 3=Planning target volume (PTV) 4=medulla, 5= pituitary,
6= hypothalamus.
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cause of changes in the planning system. The doses were
calculated at several distances from the edges, based on
results from the first seven patients and standard tables.
The photon beam quality was 6 MV. For BT the mean
dose to the hypothalamus and pituitary was recon-
structed on 3D CT slice geometry for a few typical
patients with epipharynx and tonsil tumours. The mean
BT dose to the organs of interest was then added to the
dose from the external beams (Figure 4). Tumours of the
oropharynx were treated with a low dose rate source,
while tumours of the epipharynx were treated with a high
dose rate source. The uncertainty at the 95 % confidence
level of the total mean doses to the hypothalamus and pi-
tuitary has been estimated to be approximately 15%.
Quality of life (QoL)
The QoL was assessed using four generic self-rating
questionnaires: The Symptom Check List-90 (SCL-90)
[15], the Nottingham Health Profile (NHP) [16], the Psy-
chological General Well-Being (PGWB) index [17] andthe Baecke questionnaire. SCL-90 is a 90-item multidi-
mensional self-report inventory designed to screen for a
broad range of psychological problems and symptoms of
psychopathology. With the NHP, the patients answer
“yes” or “no” to 38 questions concerning problems with
emotional reaction, sleep, energy, pain, physical mobility,
and social life. The results are used to calculate scores
for each of these domains, as well as an overall total
score. High scores denote severe problems and a low
QoL.
The PGWB contains 22 questions, the answers to
which generate both an overall score and six sub-scores
covering anxiety, depression, well-being, self-control,
health, and vitality. Patients answer each question by
selecting a number from 1 to 6, 1 being the most nega-
tive option and 6 the most positive. Therefore, in con-
trast to the NHP, low PGWB scores denote poor QoL.
Finally, the Baecke questionnaire was used to assess
daily physical activity [18]. Baecke is a self-administered
questionnaire (29 items) about habitual activities that
gives information on three factors: physical activity at
Figure 4 The sagittal view of the dose distribution of the sum of external beam radiotherapy and the brachytherapy in patients
with cancer of the epipharynx. Volumes of interest and isodose lines are presented. Abbreviations: PTV-T= Planning target volume for the
external beam.
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during leisure time excluding sport.
Biochemistry
To determine the adequacy of the hypothalamic-
pituitary axis and thyroid function, the following ana-
lyses were performed for the 48 patients participating in
the first study visit: serum insulin-like growth factor
(IGF)-I, prolactin, testosterone (in men), gonadotropins
(LH, FSH), free thyroxine, thyroid stimulating hormone
(TSH), and serum cortisol at 0900 hrs. Commercial in-
house immune assays were used for all analysis. Patients
with abnormal levels in any of these hormones were fur-
ther evaluated. The 15 patients who entered the case-
controlled study were also tested for GH deficiency
using an insulin tolerance test.
Statistics
Values are presented as mean and SD. The statistical sig-
nificance of the difference between cancer patients and
matched controls was calculated using Wilcoxon`s signed
rank test, as patients and controls were individually




All patients in the case-control study had a peak GH
response above 6.0 μg/L (abnormal response < 3μg/L).The mean response to the insulin-induced hypoglycaemia
among the patients was 13.5 μg/L, ranging between 6
and 42. The patients and controls had also similar
serum concentrations of sex steroids and free T4
(12.0 ± 0.6 vs. 12.9 ± 0.4 pmol/L) and TSH (1.40 ±
0.18 vs. 1.38 ± 0.14 mIU/L) although the thyroid hor-
mones were statistically different between the groups
(both p<0.05).
Of the 48 patients who took part in the pre-study visit,
three already had well controlled T4 replacement therapy
due to primary hypothyroidism. An additional 13
patients were diagnosed with primary hypothyroidism
during the trial (clinical signs and TSH > 4 mIU/L). Nine
of the hypothyroid patients had mild hypothyroidism
with TSH levels between 4 and 8 mI U/L. Primary
hypothyroidism was considered secondary to neck radi-
ation [19,20]. The 13 newly identified hypothyroid
patients received thyroxin replacement therapy. When
patients had been clinically and biochemically euthyroid
for at least 6 months, they were eligible to enter the case-
controlled study. Therefore, three of the newly substi-
tuted patients were included in the case-controlled study,
and a total of six patients had thyroxin replacement in
the study.
We found one patient with severe hypopituitarism
who was excluded from further analysis. No other overt
pituitary insufficiency was found during the screening
procedure. Prolactin was slightly elevated in seven indi-
viduals and slightly low in one.
Table 3 Results from the Symptom Checklist (SLC-90)
questionnaire in growth hormone sufficient adults who
have received a radiation dose towards the basal part of






Somatisation 0.647 (0.496) 0.357 (0.366) 0.005 (0.013)
Obsessive-Compulsive 0.670 (0.578) 0.447 (0.253) 0.14
Interpersonal sensitivity 0.453 (0.504) 0.313 (0.295) 0.55
Depression 0.753 (0.666) 0.190 (0.167) 0.01 (0.03)
Anxiety 0.40 (0.417) 0.27 (0.492) 0.05 (0.09)
Hostility 0.42 (0.581) 0.22 (0.308) 0.3
Phobic Anxiety 0.11 (0.168) 0.30 (0.082) 0.08
Paranoid Ideation 0.42 (0.64) 0.16 (0.181) 0.33
Psychoticism 0.19 (0.292) 0.04 (0.063) 0.16
Global severity index 0.502 (0.444) 0.243 (0.123) 0.04 (0.08)
Positive symptom
distress index
1.0 (1.73) 3.33 (11.8) 0.6
3Score given as mean value ± one standard deviation. P-values in brackets are
after the exclusion of two patients with epipharynx cancer.
Table 4 Results from the Nottingham Health Profile (NHP)
questionnaire in growth hormone sufficient adults who
have received a radiation dose towards the basal part of
4
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The median dose to the hypothalamus was 1.9 Gy (range
1.5–2.2 Gy) and the median dose to the pituitary gland
was 2.4 Gy (range 1.8–3.3 Gy) in the 13 patients with
oropharyngeal cancer. The pituitary gland is to a large
extent included in the irradiation field in the epipharynx
patients. The two patients with epipharyngeal cancer
therefore received 6.0 and 9.3 Gy to the hypothalamus
and 33.5 and 46.1 Gy towards the pituitary.
Quality of life
The Baecke questionnaire demonstrated a trend for
reduced physical activity during leisure time for patients
compared to controls (p=0.06) (Table 2).
Patients also had a significantly higher score in the
domains of somatisation, depression, anxiety, and global
severity index in the SCL-90 questionnaire, demonstrat-
ing compromised QoL in patients compared to controls
(Table 3). In the NHP domains of emotional reaction
and energy, scores were increased in patients compared
to controls, meaning that QoL was reduced in patients
(Table 4). Patients as compared with controls had
reduced PGWB scores, indicating reduced self-perceived
QoL in the domains of anxiety, depression, well being,
general health, vitality, and total scores (Table 5).
By excluding the patients with the highest doses to-
wards the basal volume of the brain (i.e., the two patients
with epipharynx cancer), three out of 12 significant find-
ings in the QoL questionnaires were lost: anxiety
(p=0.096) and global severity index (p=0.08) in the SCL-
90, and the energy score (p=0.066) in the NHP. Patients
receiving thyroxine replacement therapy for primary
hypothyroidism (n=6) had similar QOL scoring as
patients with normal thyroid function (data not shown).
Discussion
A novel finding of our study was that in long-term survi-
vors who had received radiation treatment for orophar-
ynx cancer and a low inadvertent accumulated dose
towards the basal part of the brain and the pituitary,
quality of life was compromised. In order to eliminate
several confounders, patients included were highlyTable 2 Results from the Baecke questionnaire measuring
physical activity in growth hormone sufficient adults who
have received a radiation dose towards the basal part of
the brain and matched controls2
Domains Patients n = 15 Controls n = 15 p-value
Work 2.80 (0.46) 2.76 (0.59) 0.8
Sport 2.43 (0.68) 2.83 (0.62) 0.1
Leisure 2.98 (0.56) 3.48 (0.68) 0.06
Total score 8.22 (1.31) 9.08 (1.39) 0.14
2Score given as mean value ± one standard deviation.selected well functioning patients without hypopituitar-
ism and GH deficiency.
The reason for selecting this patient group for long-
term studies of the effects of low dose radiation to-
ward the basal part of the brain and the pituitary is
that their radiotherapy has been standardised in our
unit for the last two decades. Another reason is their
favourable long-term prognosis obtained by using in-
tense multimodal treatment that has increased the
five-year survival rate, even in patients with advanced
T3 and T4 tumours in the head and neck region [14].
In this group of patients it was therefore possible to
study the biological late effects after low-dose radio-
therapeutic exposure.
The effects of low doses of ionizing radiation in infancy,
such as in the treatment of haemangioma, have recently
been studied and found to influence cognitive abilities inthe brain and matched controls
Domains Patients n = 15 Controls n = 15 p-value
Emotional reaction 7.0 (10.3) 0.0 (0.0) 0.02 (0.03)
Sleep 5.8 (10.0) 7.1 (15.3) 0.9
Energy 14.6 (23.0) 0.0 (0.0) 0.04 (0.07)
Pain 4.2 (12.0) 2.5 (9.8) 0.6
Physical mobility 1.4 (3.6) 0.7 (2.6) 0.4
Social isolation 4.7 (13.0) 0.0 (0.0) 0.2
Total score 6.3 (7.6) 1.7 (3.4) 0.08
4Score given as mean value ± one standard deviation. High scores reflect low
quality of life. P-values in brackets are after the exclusion of two patients with
epipharynx cancer.
Table 5 Results from the Psychological General Well-
Being (PGWB) questionnaire in growth hormone
sufficient adults who have received a radiation dose
towards the basal part of the brain and matched
controls5
Domains Patients n = 15 Controls n = 15 p-value
Anxiety 24.2 (5.0) 27.8 (1.7) 0.02 (0.03)
Depression 16.6 (1.5) 17.8 (0.6) 0.02 (0.03)
Well-being 16.6 (4.0) 20.0 (2.2) 0.01 (0.02)
Self consciousness 16.0 (1.8) 16.7 (1.3) 0.4
General health 14.5 (2.6) 16.6 (2.0) 0.009 (0.01))
Vitality 17.4 (4.7) 21.5 (1.5) 0.006 (0.007)
Total score 105.3 (17.2) 120.4 (6.3) 0.005 (0.006)
5Score given as mean value ± one standard deviation. P-values in brackets are
after the exclusion of two patients with epipharynx cancer.
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100 mGy [6]. Furthermore, adults treated for childhood
onset acute lymphatic leukaemia (ALL) with cranial radio-
therapy using doses of 18–20 Gy developed GH deficiency
and impaired neuropsychological performance, although
self-reported QoL was not affected [21]. Adults treated
with radiotherapy for cancer of the nasopharynx and para-
nasal sinuses show radiation-induced vascular damage and
cognitive decline at follow-up when total doses >40Gy
were administered to the temporal lobe [22]. Long-term
studies in adults who have received low-dose radiation to-
wards the brain in adulthood and where the possible neu-
roendocrine consequences have been accounted for have
not been performed previously, to our knowledge. We
therefore carefully selected patients with no detected neu-
roendocrine consequences of previous treatment. We also
excluded the presence of GH deficiency using the insulin
tolerance test.
We have in our patient group 6 of 15 patients with pri-
mary hypothyroidism, a condition that can affect QoL.
During inadequate hypothalamic stimulation the pituit-
ary may synthesise and secrete a TSH that is biologically
less active and with a longer half-life [23]. This may com-
plicate the diagnosis of hypothyroidism in this patient
population as some have received both radiation towards
the hypothalamic-pituitary areas and the thyroid gland.
However, as TSH synthesis and secretion is more resist-
ant to radiation than GH and gonadotropins [4] the
hypothalamic radiation is less likely to be a confounder
of importance in this study as all patients tested normal
for both GH and gonadotropic function. All patients with
primary hypothyroidism were also fully replenished with
T4 for more than 6 months before entering the case-
controlled trial and their thyroid hormone concentra-
tions and their QoL scoring were similar to those in the
healthy matched controls. We therefore believe that the
impact of hypothyroidism on the outcome of this study
is most likely negligible [24].In this study, we have determined the total radiothera-
peutic doses to the hypothalamus and the pituitary. The
hippocampus, which is a radiosensitive structure in the
basal part of the brain, is also of interest because it is
known that hippocampal damage might affect cognitive
function and wellbeing [25]. The hippocampal dose
could not be calculated with good accuracy in our study,
as the structure cannot be defined well enough on the
dose planning CT. We therefore assume that the hippo-
campus received approximately the same dose as the
hypothalamus, as these regions have the same distance
from the base of the skull. A volumetric study of the
hippocampus has been performed as part of the case-
control study in order to further study this possibility
[unpublished data].
Many patients treated with head and neck cancer suffer
from decreased QoL due to xerostomia, trismus, and swal-
lowing difficulties one to five years after treatment [9,10].
Only a few studies have been performed using generic
self-rating QoL questionnaires in patients with no sign of
recurrence years after treatment [11,12]. Hammerlid et al.
[10] showed that patients still suffered from functional
limitations related to the disease and its treatment three
years after diagnosis and treatment of head and neck can-
cer. However, these problems did not generally affect their
overall health-related QoL as assessed using disease spe-
cific cancer related QoL questionnaires. Others [26-28]
have also reported similar findings. Pourel et al. [12] found
that physical functioning, role of functioning, and pain
score did not differ from the general population. Their
findings indicate that coping processes strongly influence
QoL in long-term survivors of cancer. Foley et al [29]
showed, using semi-structured interviews with survivors
of several cancers more than 15 years after their diagnoses
that the majority had experienced either a positive influ-
ence or very little long-term impact on their lives demon-
strating how well cancer patients incorporate the cancer
experience into their overall life experience.
Our study addresses general well-being in long-term
head and neck cancer survivors (4–10 years) in a case-
controlled trial. We have used four generic questionnaires
that have all been previously used in various patient
groups and in the general population. Although the study
is small, the results from three independent questionnaires
consistently showed compromised QoL in patients. The
various affected domains were also consistent: depression,
anxiety, energy, and general well-being. In addition,
patients tended to have reduced physical activity during
leisure time. Previous studies on QoL in this patient group
were cross-sectional case studies, whereas our study was
designed as a case-control study also adjusting for socioe-
conomic status. We have not specifically determined the
mechanism for our findings, but a causal relationship be-
tween low-dose radiotherapy towards the basal brain and
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were minimized in the trial design.
Conclusions
We have demonstrated compromised QoL in patients
who had received a low radiation dose towards the basal
part of the brain. After eliminating many possible con-
founders, we suggest that a small amount of absorbed
radiotherapeutic dose to the basal parts of the brain has
negative long-term consequences in adults that are inde-
pendent from the neuroendocrine effects of radiation. Our
data highlights the importance of further studies on the
biological effects of low-dose radiation in normal tissue
and volumes at risk [30].
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